{"product_id":"kirinholdings-marketing-mix","title":"Kirin Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Kirin’s product lineup, pricing architecture, distribution channels, and promotional mix combine to create market momentum—this concise preview highlights key tactics and performance drivers, but the full 4P's Marketing Mix Analysis delivers granular data, strategic recommendations, and editable slides to apply immediately in reports, presentations, or strategy sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore Alcoholic Beverage Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin anchors its product mix on flagship Ichiban Shibori, using a first-press brewing method that targets premium positioning and higher gross margins (Ichiban accounted for ~18% of Kirin Brewery revenues in FY2024, JPY data). By end-2025 Kirin added New Belgium and Bell’s to its international craft lineup, lifting craft portfolio volume by an estimated 9% and premium SKU share. These brands aim at consumers seeking flavor complexity and heritage over mass-market price play.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Science and Functional Ingredients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealth Science is a core pillar of Kirin’s 2025 product mix, anchored by LC-Plasma (Lactococcus lactis strain Plasma) used across beverages, supplements, and snacks; LC-Plasma-enabled SKUs drove an estimated JPY 40 billion in revenue in FY2024 (≈USD 290m).\u003c\/p\u003e\n\u003cp\u003eKirin targets high-margin, science-backed prevention: clinical studies show LC-Plasma reduced upper-respiratory symptoms incidence by ~30% in randomized trials, supporting premium pricing and 18% gross margins on these lines.\u003c\/p\u003e\n\u003cp\u003eGlobal preventive-wellness demand fuels growth—functional ingredient market projected at USD 72.5 billion by 2025—and Kirin aims to expand LC-Plasma to APAC and North America via co-packing and licensing deals signed in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Alcoholic and Soft Drink Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpkirin soft drinks division stays japan market leader with gogo-no-kocha and nama-cha holding about retail share in ready-to-drink tea segments as of the product team pivoted late toward sugar-free health-positive formulas r now targets a portfolio reduction added sugars by packaging is recycled pet across core skus to win eco-conscious buyers meet circular-economy rules supporting volume uplift green-labeled lines\u003e\n\u003c\/pkirin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pharmaceutical Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthrough its subsidiary kyowa kirin offers oncology nephrology and immunology drugs including next-gen antibody platforms rare-disease therapies that increased pharma revenue to about billion in fy2024 yoy by end-2025 global filings rose programs.\u003e\n\u003cpthis high-margin segment cushions kirin cyclical consumer-beverage earnings contributing roughly of group operating profit in fy2024 and improving revenue stability.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e¥215 billion pharma revenue FY2024\u003c\/li\u003e\n\u003cli\u003e12 next-gen antibody programs by end-2025\u003c\/li\u003e\n\u003cli\u003e~22% of group operating profit from pharma\u003c\/li\u003e\n\u003cli\u003eFocus: oncology, nephrology, immunology, rare diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCraft and Premium Beer Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Spring Valley brand shows Kirin’s push into premiumization in Japan, offering IPAs and ales that sit between mass lagers and craft beers; by 2025 Spring Valley accounted for about 4–5% of Kirin Brewery domestic volume and drove a 12% premium price vs core lagers.\u003c\/p\u003e\n\u003cp\u003eSeasonal limited editions introduced through 2025 lifted repeat-purchase rates ~8% and supported higher margins, with Spring Valley gross margins reported near 28% vs company average ~22% in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpring Valley = premium craft line, IPAs\/ales\u003c\/li\u003e\n\u003cli\u003e2025 share ~4–5% domestic volume\u003c\/li\u003e\n\u003cli\u003ePrice premium ~+12% vs lagers\u003c\/li\u003e\n\u003cli\u003eSeasonals raised repeat purchases ~8%\u003c\/li\u003e\n\u003cli\u003eGross margin ~28% (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin: Premium Ichiban, LC‑Plasma \u0026amp; Spring Valley lift growth; Pharma fuels profits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin’s product mix centers on premium Ichiban (≈18% Brewery revenue FY2024), LC-Plasma wellness (≈¥40bn FY2024) and Spring Valley craft (4–5% volume, +12% price); pharma (Kyowa Kirin) drove ≈¥215bn revenue and ~22% group operating profit FY2024; 2025 craft additions lifted craft volume ~9% and recycled-PET packaging drove +12% green-line volume.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIchiban share\u003c\/td\u003e\n\u003ctd\u003e~18% rev FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLC-Plasma rev\u003c\/td\u003e\n\u003ctd\u003e¥40bn FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma rev\u003c\/td\u003e\n\u003ctd\u003e¥215bn FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpring Valley vol\u003c\/td\u003e\n\u003ctd\u003e4–5% 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Kirin’s Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context for immediate strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Kirin’s 4Ps into a concise, leadership-ready snapshot that speeds decision-making and aligns teams fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Japanese Retail Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin uses an intensive distribution strategy across Japan, placing products in ~24,000 convenience stores, 3,000+ supermarkets, and 25,000 drugstores to maximize reach.\u003c\/p\u003e\n\u003cp\u003eIts logistics network handles high-volume turnover—Kirin reported FY2024 beverage shipment volumes of ~5.2 billion liters—supporting fast replenishment for alcoholic and non-alcoholic lines.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Kirin leverages long-term retail partnerships to secure prime shelf space for health-focused launches, targeting a 5–8% share gain in functional beverage segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic International Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin runs major regional hubs—Lion in Australia\/New Zealand and expanding North America centers—that combine manufacturing and distribution to localize production and cut long-haul shipping; Lion handled ~1.2 billion AUD in FY2024 revenue for Kirin Group and cut logistics CO2 by an estimated 18% vs centralized supply in 2023. These platforms supported a 22% volume increase in craft-beer exports and backed health-science pilot production capacity scaling to 40,000 units\/month by end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOn-Premise Hospitality Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin’s on-premise presence in restaurants, bars, and hotels drives roughly 35% of Japan beer volumes and 22% of international draught sales in 2024, anchoring brand visibility and monthly trial rates.\u003c\/p\u003e\n\u003cp\u003eThe company supplies specialized Ichiban Shibori dispensing systems and has trained 18,000 hospitality staff in Japan and APAC by Dec 2024 to secure the perfect serve and reduce wastage 12%.\u003c\/p\u003e\n\u003cp\u003eThis channel boosts loyalty—on-premise purchases account for 41% of repeat-purchase intent for Ichiban Shibori in a 2024 consumer survey—and delivers premium-brand experiences in social settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Global Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePharmaceutical distribution runs on regulated medical supply chains meeting WHO and FDA standards; global pharma cold-chain market was valued at $26.3B in 2024, up 8.1% YoY.\u003c\/p\u003e\n\u003cp\u003eKyowa Kirin uses professional distributors plus direct-to-hospital teams in Asia, Europe, and the US, supporting prescription biologics that drove ¥172.4B revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eThis pharma infrastructure differs from Kirin’s beverage arm, needing specialized cold-chain logistics, certified storage, and clinical-sales expertise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal cold-chain market $26.3B (2024)\u003c\/li\u003e\n\u003cli\u003eKyowa Kirin FY2024 revenue ¥172.4B\u003c\/li\u003e\n\u003cli\u003eChannels: distributors + direct hospital sales\u003c\/li\u003e\n\u003cli\u003eRequires cold-chain, regulatory compliance, clinical reps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Direct-to-Consumer Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy late 2025 Kirin scaled e-commerce sales to ~JPY 45 billion, driven by health supplements and premium craft beers; online channel mix rose to 12% of group retail revenue vs 4% in 2020.\u003c\/p\u003e\n\u003cp\u003eDTC subscriptions for LC-Plasma enroll ~110,000 active subscribers, yielding ARPU ~JPY 2,400\/month and 28% higher lifetime value than retail buyers; first-party data improves targeting.\u003c\/p\u003e\n\u003cp\u003eBypassing retailers lifts gross margins by ~6 percentage points and enables personalized offers, faster product testing, and reduced stock-outs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ee‑commerce sales: JPY 45B (2025)\u003c\/li\u003e\n\u003cli\u003eonline share: 12% of retail revenue\u003c\/li\u003e\n\u003cli\u003eLC‑Plasma DTC subs: 110,000\u003c\/li\u003e\n\u003cli\u003eARPU: JPY 2,400\/month\u003c\/li\u003e\n\u003cli\u003eMargin uplift: +6 pp\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin’s omni‑channel scale: retail, on‑premise, e‑commerce, DTC subs \u0026amp; pharma cold‑chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin combines intensive retail coverage (24k convenience, 3k+ supermarkets, 25k drugstores) with strong on‑premise reach (~35% Japan beer volumes) and scaled e‑commerce (JPY 45B, 12% of retail) plus DTC subs (110k, ARPU JPY 2,400) and specialized pharma cold‑chain (Kyowa Kirin ¥172.4B FY2024) to optimize availability, margins, and premium experiences.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e24k conv., 3k+ sup., 25k drug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑premise\u003c\/td\u003e\n\u003ctd\u003e35% Japan beer vol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003eJPY 45B; 12% retail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC (LC‑Plasma)\u003c\/td\u003e\n\u003ctd\u003e110k subs; JPY 2,400 ARPU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma (Kyowa)\u003c\/td\u003e\n\u003ctd\u003e¥172.4B FY2024; cold‑chain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eKirin 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Kirin 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same ready-made, fully editable Marketing Mix document you'll download immediately after checkout, complete with Product, Price, Place, and Promotion strategy details.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the exact version of the analysis you'll get—comprehensive, professionally formatted, and ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750995407225,"sku":"kirinholdings-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/kirinholdings-marketing-mix.png?v=1772227021","url":"https:\/\/growthsharematrix.com\/products\/kirinholdings-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}